Editas Medicine (EDIT) Income towards Parent Company (2015 - 2025)

Editas Medicine (EDIT) has 11 years of Income towards Parent Company data on file, last reported at -$30.3 million in Q3 2025.

• On a quarterly basis, Income towards Parent Company rose 51.28% year-over-year to -$30.3 million in Q3 2025; TTM through Dec 2025 was -$161.1 million, a 36.51% increase from a year earlier, with the FY2024 full-year figure at -$255.5 million, up 46.79% from the prior year.
• Income towards Parent Company for Q3 2025 stood at -$30.3 million, up from -$52.0 million in the prior quarter.
• Over the last five years, Income towards Parent Company for EDIT reached as high as -$20.4 million in Q4 2023 and fell as low as -$4.0 billion in Q1 2022.
• Historically, Income towards Parent Company has averaged -$444.9 million across 5 years, with a median of -$67.6 million in 2024.
• Across the five-year window, Income towards Parent Company tumbled 3901.13% in 2022 and jumped 92.91% in 2023, its largest moves.
• Year by year, Income towards Parent Company stood at -$33.7 million in 2021, then sank by 71.62% to -$57.9 million in 2022, then soared by 64.7% to -$20.4 million in 2023, then plunged by 184.76% to -$58.2 million in 2024, then soared by 47.95% to -$30.3 million in 2025.
• Per Business Quant data, the three most recent Income towards Parent Company figures were -$30.3 million in Q3 2025, -$52.0 million in Q2 2025, and -$78.9 million in Q1 2025.